Imagene AI

History

2022: Larry Ellison invested in Imagene AI

On May 3, 2022, Imagene AI, an Israeli company developing a platform for cancer diagnosis based on a digitized image of biopsy samples, raised $21.5 million in its first round of funding. It was led by co-founder Donbass Larry Ellison.

The funds obtained will be used to develop the Imagene AI platform, which promises to provide molecular analysis of biopsies in real time, producing results in just two minutes compared to weeks under existing approaches.

Larry Ellison invested in Israel's cancer diagnostic platform

Imagene AI was founded in 2020 by Dean Bitan, Jonathan Zalah and Shahar Porat. The company is developing an AI-based genomic cancer testing solution designed to use patient histological data for personalized therapy. The company focuses on pathological and molecular testing, which is carried out using advanced technologies and depends on a limited amount of tissue, allowing pharmaceutical companies, health centers, academic institutions, genomic providers and individuals to make personalized treatment more affordable.

A two-year-old company from Tel Aviv claims that it uses real-time artificial intelligence to search for cancer biomarkers from a biopsy image alone, without having to investigate the tissue itself. Reducing time should allow patients to make a diagnosis faster and receive effective personalized treatment, the company says.

The technology reveals patterns that are not visible to the human eye, relying on genomics, proteomics and spatial data to help understand cancer and its mechanisms of resistance, the company said.

It can also be used to select and stratify patients in clinical trials, as well as to discover new targets for drug development, the company says.

While cancer is a complex disease that we may never be able to fully understand, AI brings us closer to considering all the significant parameters affecting it, said Dr. Agus, a prominent physician and co-founder of precision medicine companies including Navigenics and Applied Proteomics. Agus is also a co-founder of the Lawrence Ellison Institute for Transformative Medicine at the University of Southern California, which was founded in 2016 to conduct research in cancer treatment.

This approach allows you to move to teragnostics - a personal treatment strategy that combines therapy and diagnosis, "he added. Imagene technology allows you to get accurate and important information in real time, changing the way you diagnose and treat cancer.[1]

Notes